What is the detailed CALGB (Cancer and Leukemia Group B) MTR (Methotrexate‑based) protocol for treating newly diagnosed primary central nervous system lymphoma in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

CALGB MTR Protocol for Primary CNS Lymphoma

The CALGB MTR protocol refers to a methotrexate-based regimen (MTX, procarbazine, vincristine) that was historically used for PCNSL, but has now been superseded by more intensive modern regimens like MATRix, which demonstrate superior survival outcomes. 1

Historical Context: The Original MTR Protocol

The CALGB MTR regimen consisted of:

  • High-dose methotrexate 3.5 g/m²
  • Procarbazine 100 mg/m²/day
  • Vincristine 1.4 mg/m²

This was administered for 5 cycles as induction chemotherapy, followed by whole-brain radiotherapy (45 Gy) in younger patients, with some protocols adding high-dose cytarabine after radiation 2. The regimen achieved a 90% objective response rate and median overall survival of 60 months in the original study 2.

Why This Protocol Is No Longer Standard

Current 2024 EHA-ESMO guidelines do not recommend the original CALGB MTR protocol as first-line therapy because more intensive regimens have demonstrated significantly better outcomes. 1

The evolution away from MTR occurred because:

  • MATRix regimen (methotrexate-cytarabine-rituximab-thiotepa) achieved 7-year overall survival of 56% versus 26% with methotrexate-cytarabine alone in the IELSG32 trial 1
  • When MATRix was followed by consolidation (ASCT or WBRT), 7-year OS reached 70% 1
  • The addition of high-dose cytarabine and thiotepa provides superior CNS penetration and disease control compared to procarbazine-vincristine combinations

Current Standard: Modern MTX-Based Protocols

For newly diagnosed PCNSL in fit patients (age ≤65 years with ECOG PS 0-3, or age ≤70 years with ECOG PS ≤2), the recommended approach is: 1

Induction Phase

MATRix regimen (preferred):

  • High-dose methotrexate ≥3 g/m² (3-4 hour infusion)
  • High-dose cytarabine 2 g/m² every 12 hours × 2 days
  • Rituximab (though not FDA/EMA approved; discuss risks/benefits)
  • Thiotepa

Alternative regimens include:

  • R-MBVP (rituximab-methotrexate-carmustine-etoposide-methylprednisolone) followed by HD-cytarabine
  • R-MPV (rituximab-methotrexate-procarbazine-vincristine) - this is the modern evolution of the original MTR protocol 1

Consolidation Phase

For eligible patients: Thiotepa-based high-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) 1

For patients ineligible for ASCT: Reduced-dose whole-brain radiotherapy (23.4 Gy) or standard-dose WBRT (36-40 Gy) in younger patients 1

Critical Dosing Requirements

Methotrexate must be administered at ≥3 g/m² to achieve adequate CNS penetration 1. Some experts recommend:

  • Initial 500 mg/m² bolus over 15 minutes
  • Followed by remaining dose over 2-4 hours
  • Leucovorin rescue starting 24 hours post-infusion 3

Important Caveats

  • 62% of patients receiving MATRix complete all 4 planned cycles, but 75% require dose reductions 1
  • Treatment-related mortality with MATRix is approximately 6% 1
  • Whole-brain radiotherapy at standard doses (36-40 Gy) should be avoided in elderly patients due to severe neurocognitive toxicity risk 1
  • Rituximab remains controversial; HOVON 105 trial showed no clear benefit, while IELSG32 demonstrated improved PFS/OS with its addition 1

For Unfit/Elderly Patients

When intensive chemotherapy is not feasible, consider:

  • Reduced-dose methotrexate regimens
  • Oral alkylating agents (temozolomide, procarbazine) with rituximab
  • Palliative WBRT (30-36 Gy)
  • Best supportive care in very frail patients 1

The key message: While the CALGB MTR protocol was groundbreaking in establishing methotrexate-based therapy for PCNSL, current evidence strongly supports more intensive regimens incorporating high-dose cytarabine and thiotepa for eligible patients. 1

References

2
Research

Treatment for primary CNS lymphoma: the next step.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000

Related Questions

In a 50‑year‑old man with bulky diffuse large B‑cell lymphoma who develops tumor‑lysis syndrome after the first R‑CHOP cycle, which drug should be used prophylactically to prevent this presentation?
In a 66‑year‑old patient with ovarian diffuse large B‑cell lymphoma being evaluated for possible CNS involvement, should a non‑contrast CT of the brain and cervical spine be performed prior to a lumbar puncture?
In a patient with diffuse large B‑cell lymphoma and a bulky mass/high tumor burden, can rituximab precipitate tumor‑lysis syndrome, and should CHOP be given before rituximab?
How is the International Extranodal Lymphoma Study Group (IELSG) prognostic score calculated for primary central nervous system lymphoma (PCNSL) and how does it guide treatment decisions?
What is the International Extranodal Lymphoma Study Group (IELSG) prognostic score for primary central nervous system (CNS) lymphoma?
In an elderly patient with heart failure secondary to myocardial infarction and diabetes, what is the most appropriate treatment?
What is the appropriate treatment for muscle spasms in a patient aged 80 years or older?
In a patient who cannot tolerate metformin and is already on insulin with an HbA1c of 10%, what additional diabetes medication can be added?
Can gabapentin cause fever, and what is the underlying mechanism?
What diagnostic workup and case sheet should be prepared for an adult with a one‑month history of urticaria (hives) and lip angioedema associated with acute hepatitis?
Can tadalafil or vardenafil cause photophobia, and can dose reduction alleviate it?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.